Poet: William Carlos Williams
Poem: The Crowd At The Ball Game
Poem of the Day:
Mar 18 2008
Comment 14 of 14, added on May 26th, 2013 at 9:26 AM.
NASCAR drivers recall Dick Trickle as unique and fun - USA Today
STOCKHOLM, Sweden, May 17 (UPI) -- In utero exposure to depression medications may increase the risk of autism spectrum disorders in less than 1 percent of cases, researchers in Sweden say.
First author Dheeraj Rai, a clinical lecturer at the Department of Public Health Sciences at Karolinska Institutet in Stockholm, and colleagues at the University of Bristol; Avon and Wiltshire Partnership Mental Health NHS Trust in Bristol, England; and Drexel University School of Public Health on Philadelphia said the study involved 4,429 cases of autism spectrum disorder -- 1,828 with and 2,601 without intellectual disability and 43,277 age and sex matched controls.
The study involved 1,679 cases of autism spectrum disorder and 16,845 controls with data on maternal anti-depressant use.
The study, published in the British Medical Journal, said parental depression and other characteristics were recorded in administrative registers before the birth of the child. Maternal anti-depressant use, recorded at the first antenatal interview, was available for children born from 1995 onwards.
A history of maternal -- but not paternal -- depression was associated with an increased risk of autism spectrum disorders in offspring, the study said. In the subsample with available data on drugs, this association was confined to women reporting anti-depressant use during pregnancy irrespective of whether selective serotonin reuptake inhibitors or non-selective monoamine reuptake inhibitors were reported, the study said.
"Whether this association is causal or reflects the risk of autism with severe depression during pregnancy requires further research," the study authors wrote in the study. "However, assuming causality, anti-depressant use during pregnancy is unlikely to have contributed significantly towards the dramatic increase in observed prevalence of autism spectrum disorders as it explained less than 1 percent of cases."
Comment 13 of 14, added on May 26th, 2013 at 2:37 AM.
Keegan Bradley has 3-stroke lead at Nelson - USA Today
The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.
Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.
Xofigo is being approved more than three months ahead of the product¡¯s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency¡¯s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.
¡°Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,¡± said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA¡¯s Center for Drug Evaluation and Research. ¡°Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.¡±
In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.
Xofigo¡¯s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.
The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo¡¯s ability to extend overall survival.
The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).
Comment 12 of 14, added on May 26th, 2013 at 2:05 AM.
Mass. Senate hopeful refers to Newtown in campaign ad - USA Today
Stocks continued their climb into uncharted territory on Friday, racking up the fourth week in a row of gains as encouraging economic data prompted investors to buy shares of growth companies.
The Dow Jones industrial average and the Standard & Poor¡¯s 500-stock index finished at highs, driven by gains in energy and industrial shares. The indexes have pushed to a series of high levels as part of the rally that has lifted equities more than 16 percent for the year so far.
The Dow Jones industrial average gained 121.18 points, or 0.80 percent, to close at a milestone 15,354.40. The S.& P. 500-stock index rose 17 points, or 1.03 percent, to end at a record 1,667.42.
The Nasdaq composite index climbed 33.73 points, or 0.97 percent, to finish at 3,498.97 ¡ª its highest close since October 2000.
In a sign of how far the market has come, the S.& P. 500 is about 1,000 points above the low it hit in March 2009 in the wake of the credit crisis and recession.
¡°It¡¯s hard to hold this market down,¡± said Michael Sheldon, chief market strategist at RDM Financial in Westport, Conn.
Data released on Friday showed Americans felt better about their economic and financial prospects in early May, with consumer sentiment at its highest in nearly six years, while a gauge of future economic activity rose in April to a near five-year high.
¡°If you believe the economy is going to gradually get better and that global growth will improve, the parts of the market that have not benefited so far, like cyclicals, will probably be the next group to outperform,¡± Mr. Sheldon said. Cyclical industries are those that do well when times are good, like an airline that benefits from more people flying on vacation.
The S.& P. energy sector index gained 0.8 percent, with Exxon Mobil up 1.2 percent at $91.76.
Boeing shares led the S.& P. 500¡¯s industrial sector index higher with a 2.4 percent advance to $98.92, its highest since October 2007. The S.& P. industrial index rose 1.4 percent.
The rate of growth in the economy has been expected to slow in the second quarter as tighter fiscal policy started to take effect. But recent improvements, including in the labor market and retail sales, suggest the recovery remains resilient.
¡°We are still recovering,¡± said Doreen Mogavero, chief of Mogavero, Lee & Company in New York, who also noted that the comeback was slow. She added that markets in the United States, for all their troubles, were ¡°still the best place to be at this moment.¡±
Earlier in Friday¡¯s session, the Dow touched a high at 15,357.40. For the week, the Dow advanced 1.7 percent, while the S.& P. 500 climbed 2.1 percent and the Nasdaq rose 1.9 percent.
J. P. Morgan raised its year-end target for the S.& P. 500 to 1,715 from 1,580, implying a gain of just under 3.5 percent for the index for the rest of the year.
¡°We realize investors are apprehensive about making fresh money purchases, but we see the risk/reward as particularly attractive in technology, health care and financials,¡± said the client note from Thomas Lee, J. P. Morgan¡¯s United States equity strategist.
J. C. Penney shares lost 4.2 percent to $18.01 after the retailer reported another steep quarterly loss on weak sales and heavy clearance deals, and the chief executive, Myron Ullman, cautioned that he needed time to fix the company¡¯s problems.
Tableau Software, a maker of data analysis software, surged in its first day of trading as investors bet the rising interest in Big Data would drive its growth. Tableau surged 64 percent to $50.75.
The price of the benchmark 10-year Treasury note fell 22/32 to 98 5/32, increasing the yield to 1.95, from 1.88 on Thursday.
Are you looking for more information on this poem? Perhaps you are trying to analyze it? The poem, The Crowd At The Ball Game, has received 14 comments. Click here to read them, and perhaps post a comment of your own.